A growing number of clinical observations and experimental research involving animals shows that the FGF23 serum level increases significantly in chronic kidney disease much earlier than previously used biomarkers (creatinine, phosphates, vitamin D and PTH) [10]. This evidence concerns the gene PTH and chronic kidney disease.